Back to news

Viatris Completes Acquisition of Pacira BioSciences

PR Newswire•17/11/2026•08:50 ET
0

Key Highlights

  • ➤Viatris (VTRS) completed its acquisition of Pacira (PCRX) for $36.50 per share in cash
  • ➤Approximately 32.93 million Pacira shares, or 66.46% outstanding, were validly tendered
  • ➤Pacira became a wholly owned Viatris subsidiary following the Section 251(h) merger
  • ➤Acquisition expected to contribute $90 million-$100 million in total revenue through December 31, 2026
  • ➤Pacira shares will be delisted from the Nasdaq Global Select Market

Expert Statements

Scott A. Smith, CEO of Viatris

“Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business.”

Scott A. Smith, CEO of Viatris

“With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management.”

Scott A. Smith, CEO of Viatris

“We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.”

Viatris Completes Acquisition of Pacira BioSciences PR Newswire

PITTSBURGH, Nov. 17, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), a leader in non-opioid pain management. The transaction was first announced on Oct. 8, 2026.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in